The Sunday biotech signal
Cardiovascular evidence deepens. Specialized work stays broad.
Three ESC updates sharpen late-stage evidence and trial execution, while Sunday's hiring pulse spans manufacturing, clinical, research, quality, commercial, and data work.
JobReports original editorial image
344
Active biopharma jobs added
26
Biopharma employers
+21.1%
Versus last Sunday
66
Manufacturing & operations roles
This dated issue is part of the public report archive. See the service update for account availability.
Cardiomyopathy / Phase 3 follow-on
Aficamten's evidence package gets more granular
Cytokinetics reported additional analyses from ACACIA-HCM and MAPLE-HCM, two completed Phase 3 studies of aficamten across non-obstructive and obstructive hypertrophic cardiomyopathy.
A prespecified exploratory ACACIA-HCM analysis described cardiac structure and diastolic-function measures at week 36 and end of treatment, with median end-of-treatment exposure of 49 weeks. MAPLE-HCM added a post-hoc view by patients' pre-trial therapy.
Why it matters
These are additional exploratory and post-hoc analyses—not new primary-endpoint results or a regulatory decision. They expand the evidence workload around an advanced cardiovascular program, especially in clinical science, biostatistics, publications, medical affairs, and regulatory preparation.
Gene therapy / Phase 2 execution
GenePHIT shows multinational trial execution at scale
AskBio completed enrollment in GenePHIT, randomizing more than 170 participants across 64 sites in 12 countries. The Phase 2 heart-failure study is randomized, double-blind, and placebo-controlled.
The update covers baseline characteristics and operational feasibility, not treatment performance. Umiposgene parvec remains investigational, and initial safety and efficacy outcomes are expected in the first half of 2027.
RNAi / Cardiovascular lifecycle
Alnylam broadens its ESC follow-on analyses
A prespecified HELIOS-B subgroup analysis examined vutrisiran outcomes with or without tafamidis at baseline. Alnylam also presented post-hoc ATTR-CM analyses and a pooled look across four Phase 3 studies.
A separate KARDIA-3 Phase 2 subgroup analysis examined zilebesiran in uncontrolled hypertension. The release adds lifecycle evidence; it does not announce a new primary-trial result or regulatory action.
Sunday hiring stays broad
JobReports added 344 active biotechnology and pharmaceutical opportunities from 26 employers between midnight Eastern and today's cutoff. That is about 21.1% above the comparable Sunday window one week earlier. Manufacturing and operations led the named role families, followed by commercial and business work.
These are active opportunities first captured by JobReports before cutoff, not employer-supplied posting times. Role-family and location classifications are directional.
38
U.S.-remote roles
11
Rahway roles
10
North Wales roles
Editor's shortlist
Five roles worth a closer look
Principal Scientist--Pharmacokinetics, Dynamics and Metabolism
Groton, Connecticut · Onsite
Associate Director, Clinical Sciences, Oncology
Cambridge, Massachusetts
Associate Development Engineer
Warsaw, Indiana · Hybrid
Associate Director - Predictive Science & AI US Commercial
Cambridge, Massachusetts · Hybrid
Associate Director, GxP Operations Support Manufacturing Systems
Boston, Massachusetts
The takeaway
Follow-on evidence keeps cross-functional work moving.
Exploratory and subgroup analyses are less visible than primary readouts, but they create real work in clinical science, biostatistics, medical affairs, trial operations, and regulatory planning. Today's verified openings extend that pattern into ADME, oncology development, medtech R&D, commercial AI, and digital manufacturing.